Laurence de Schoulepnikoff

Directeur des opérations chez OSE IMMUNOTHERAPEUTICS

Health Technology

Consumer Services

Commercial Services

Postes actifs de Laurence de Schoulepnikoff

Sociétés	Poste	Début	Fin
OSE IMMUNOTHERAPEUTICS	Directeur des opérations	16/01/2022	-
OSE IMMUNOTHERAPEUTICS	Corporate Officer/Principal	20/12/2021	16/01/2022
Swiss Healthcare Licensing Group	Directeur/Membre du Conseil	-	-
Tridek-One Therapeutics SAS Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff.	Directeur Général	-	-

Sociétés	Poste	Début	Fin
Amal Therapeutics SA Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland.	Directeur des opérations	01/01/2019	-

École Polytechnique Fédérale de Lausanne

Graduate Degree

Internationale

Suisse	4
France	3

Opérationnelle

Chief Operating Officer	2
Corporate Officer/Principal	1
Graduate Degree	1

Sectorielle

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés cotées	1
OSE IMMUNOTHERAPEUTICS	Health Technology

Entreprise privées	3
Amal Therapeutics SA Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland.	Health Technology
Swiss Healthcare Licensing Group
Tridek-One Therapeutics SAS Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff.	Commercial Services